Development of anti-ceramide scfv as mitigator of the radiation GI syndrome

Active Project Grant Awarded Last action

Award ID
R44AI106283
Recipient
Awarding agency
Obligated
$9,981,041

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 98% complete
Originally
Place of performance
New York, NY 10013, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $992,960
Amendment $992,960
Amendment $1,002,340
Amendment Non-clinical pharmacology of CX-01 - development of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as… $1,002,340
Amendment $0
Amendment $0
Amendment Non-clinical pharmacology of CX-01 - development of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as… $1,011,743
Amendment $1,011,743
Amendment $1,011,743
Amendment $0
Amendment $0
Amendment $994,084
Amendment $968,115
Amendment $0
Original award $993,013
Show all 16

Subawards

Subrecipient Amount Awarded
Sloan-Kettering Institute For Cancer Research Develop a partial body irradiation mouse model. Use the newly developed model to evaluate efficacy of a lead anti-ceramide compound. $424,800
Sloan-Kettering Institute For Cancer Research $424,800
Sloan-Kettering Institute For Cancer Research $424,800

Quick answers

Who received award R44AI106283?

R44AI106283 was awarded to Ceramedix Holding, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2014.

How much is award R44AI106283 worth?

$9,981,041 has been obligated on R44AI106283.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login